Alphagan

Quick links to important sections

Alphagan

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alphagan

What is Alphagan? The Identity and Purpose of Brimonidine

Property Description
Active Ingredient Brimonidine (as Brimonidine Tartrate)
Form Ophthalmic Solution (Eye Drops)
Pharmacological Class Selective Alpha-2 Adrenergic Agonist
Common Use Managing elevated Intraocular Pressure (Prescription Status)
Origin Synthetic

What Type of Medicine is Alphagan?

Alphagan is a prescription pharmaceutical preparation delivered as an ophthalmic solution, whose primary active ingredient is Brimonidine (specifically Brimonidine Tartrate). This compound is a synthetic, single-ingredient molecule classified as a selective alpha-2 adrenergic agonist, a designation reflecting its targeted action on receptors in the eye. Pharmacological studies have supported its role, and it is clinically recognized as an ocular antihypertensive agent. The medicine's core purpose is to actively work against high fluid pressure inside the eyeball, a critical factor in eye health management.


Alphagan's Form and Core Composition

The medicine is supplied exclusively as an ophthalmic solution, a sterile, aqueous solution designed for direct, topical ocular administration. The core composition centers on Brimonidine Tartrate, dissolved within this water-based vehicle. A key distinguishing feature of the Alphagan brand and its variants, such as Alphagan P, is the use of specific preservative systems, which is a strategic design choice at the brand level. This local delivery format is essential for its therapeutic function, ensuring the pressure-reducing agent is delivered immediately to the target structures inside the eye.


What is the General Purpose of Brimonidine?

The overarching purpose of the Brimonidine compound in this prescription formulation is to reliably reduce and manage high intraocular pressure. This function places it firmly within the category of ocular antihypertensive agents. The drug achieves this via a dual mechanism—influencing both the rate at which internal fluid (aqueous humor) is produced and the efficacy of its removal. This dual action provides a predictable, non-systemic method for localized pressure control, which is the fundamental benefit provided by the medicine.

Regulatory References

  1. NIH MedlinePlus on Brimonidine

What side effects are possible with Alphagan?

Possible Side Effects and Safety Information

The safety profile of Alphagan (brimonidine) is defined by official regulatory documents, detailing adverse reactions by frequency and affected body system. This section reports only the officially documented effects and safety constraints.


Adverse Reaction Classifications

Classification Examples of Documented Effects
Very Common (ge 1/10) Ocular hyperaemia, burning/stinging, foreign body sensation, eye pruritus, oral dryness, headache, drowsiness, fatigue, and allergic conjunctivitis.
Common (ge 1/100 to < 1/10) Dizziness, abnormal taste, blurred vision, ocular dryness, asthenia (weakness), upper respiratory symptoms, and localized eyelid irritation.
Uncommon to Very Rare Systemic allergic reactions, depression, palpitations/arrhythmias (including bradycardia and tachycardia), hypertension, hypotension, and syncope (fainting).

Adverse reactions are grouped by System-Organ Class (SOC) in regulatory texts, including Eye Disorders, Nervous System Disorders, General Disorders, and Cardiac/Vascular Disorders.


Serious Adverse Reactions and Special Populations

Serious Adverse Reactions: In post-marketing surveillance, severe systemic central nervous system depression, including apnea, bradycardia, hypotension, and respiratory depression, has been reported in neonates and infants following exposure.

Population Safety Constraints:

  • Neonates and Infants (Under 2 Years): Use is contraindicated due to the risk of severe systemic events.
  • Pediatric Patients (Ages 2 to 7): Must be used with caution and close monitoring due to the high incidence of somnolence (drowsiness), which is more frequent in those weighing le 20 kg.
  • Pre-existing Conditions: Caution is required in patients with severe cardiovascular disease, depression, cerebral or coronary insufficiency, Raynaud's phenomenon, or orthostatic hypotension.

Safety-Related Restrictions:

The medicine is contraindicated in individuals with a known hypersensitivity to any component and in patients concurrently receiving Monoamine Oxidase (MAO) inhibitor therapy or certain antidepressants that affect noradrenergic transmission.

Overdose and Emergency Response

Alphagan Overdose and When to Seek Help

If you suspect an overdose of Alphagan (brimonidine tartrate ophthalmic solution), it is crucial to seek emergency medical attention immediately. An overdose may occur from accidental ingestion, particularly in children, or from excessive ocular use.

Potential Symptoms of Systemic Overdose

Systemic absorption of brimonidine, especially in young children, can lead to serious central nervous system and cardiorespiratory effects. Symptoms are typically more severe in infants and children than in adults. In the event of an overdose, be alert for the following signs:

Systemic Effects in Adults/Children Severe Effects in Infants/Young Children
Drowsiness or lethargy Apnea (temporary cessation of breathing)
Low blood pressure (hypotension) Bradycardia (slow heart rate)
Slow heart rate (bradycardia) Respiratory depression
Pinpoint pupils (miosis) Hypotonia (loss of muscle tone)
Dizziness or fainting (syncope) Coma

When to Seek Immediate Help

Contact your local Poison Control Center or emergency medical services right away if you or someone else has swallowed Alphagan eye drops. Even if you only used too much in the eye, or if you suspect accidental ingestion, do not wait for symptoms to develop. While topical ocular overdose may be managed by rinsing the eye with water, any systemic exposure requires urgent professional assessment due to the risk of life-threatening complications.

Therapeutic Uses of Alphagan

Brimonidine, the active ingredient in Alphagan, is a prescription treatment primarily used to manage specific eye conditions by helping to control pressure within the eye. The solution is indicated for use in managing intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Targeting Elevated Eye Fluid Pressure

Alphagan is applied across domains where additional symptomatic support is needed to manage a systemic imbalance related to eye fluid. It helps address symptoms linked to organ-specific functional stress by providing supportive relief when symptoms create noticeable physiological strain. It is commonly used in clinical settings marked by temporary physiological imbalance.

Quick Fact: Support for High Eye Pressure This medication is commonly used to help with conditions characterized by periods of heightened symptoms related to the internal pressure of the eye.


Supportive Management for Glaucoma

This medication is commonly used across conditions presenting with acute or disruptive episodes, such as open-angle glaucoma. It supports patients during phases of increased discomfort and supports the patient in maintaining a sense of stability in clinical settings where symptoms become more noticeable.

“Offers symptomatic relief that helps patients cope more steadily with difficult episodes and contributes to improved day-to-day comfort during symptomatic periods.”


Supporting Long-Term Eye Function

Alphagan may be part of symptomatic management in contexts marked by increased discomfort or tension on the optic nerve. It offers symptomatic relief that helps patients cope more steadily with symptom fluctuations and contributes to easing the overall symptom load to support general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Eligibility Profile: Official Regulatory Status

Alphagan (Brimonidine Tartrate Ophthalmic Solution) eligibility is strictly defined by government regulatory agencies, which determine who is permitted, restricted, or prohibited from using the medicine.

Category Regulatory Status
Absolute Contraindications Neonates and infants (under 2 years old), hypersensitivity to any component, and patients receiving Monoamine Oxidase (MAO) Inhibitor therapy or specific antidepressants [Source 1.2, 1.7].
Restricted/Cautionary Use Children aged 2 to 7 years must be treated with caution due to the high reported incidence of somnolence (drowsiness) [Source 2.4]. Caution is also advised for patients with severe cardiovascular disease, depression, cerebral or coronary insufficiency, or vascular insufficiency syndromes (e.g., Raynaud's phenomenon) [Source 1.6].
Established Populations Adults and Older Adults (Geriatric patients) [Source 1.2]. No dosage adjustment is required for the elderly [Source 3.4].
Pregnancy and Lactation Pregnancy: Use only if the potential benefit outweighs the potential risk to the fetus [Source 1.1]. Lactation: Use is generally not recommended in nursing mothers [Source 2.7].
Organ Function Status Use is not established in patients with hepatic or renal impairment, as clinical studies have not been performed in these populations [Source 3.4].

What should I know about interactions with other medicines?

Alphagan (brimonidine tartrate ophthalmic solution) has specific documented interactions with certain medicinal products and classes of agents, primarily due to the potential for additive effects or interference with systemic drug metabolism.

Contraindicated Combinations

Alphagan is contraindicated for use with Monoamine Oxidase (MAO) Inhibitors and with antidepressants that affect noradrenergic transmission (e.g., tricyclic antidepressants and mianserin). Concurrent use is restricted because MAO inhibitors may theoretically interfere with the metabolism of brimonidine, potentially leading to increased systemic side-effects such as hypotension. Additionally, tricyclic antidepressants may blunt the hypotensive effect of systemic clonidine, and while it is unknown if this interferes with the ocular pressure-lowering effect, caution is advised.

Cautionary Combinations

The possibility of an additive or potentiating effect must be considered when Alphagan is used with other Central Nervous System (CNS) Depressants, including alcohol, barbiturates, opiates, sedatives, and anesthetics. Because Alphagan may reduce blood pressure, caution is advised when co-administering it with systemic antihypertensives and/or cardiac glycosides.

Caution is also advised when initiating or changing the dose of any systemic agent that may interact with alpha-adrenergic agonists or interfere with their activity, such as reserpine, methylphenidate, or chlorpromazine.

Procedural and Timing-Based Constraints

If more than one topical ophthalmic drug product is used, the different products should be administered at least five minutes apart. The preservative in the solution, benzalkonium chloride, can be absorbed by soft contact lenses. Therefore, lenses must be removed prior to application, and should not be reinserted for at least 15 minutes after instilling the solution.

Mechanism of Action

How Alphagan Works

Alphagan functions as a highly selective alpha-2 (alpha2) adrenergic agonist, binding to and activating these receptors primarily on the ciliary epithelium of the eye. This targeted interaction initiates a G-protein coupled cascade that leads to the inhibition of adenylyl cyclase. Consequently, intracellular levels of the signaling molecule cyclic AMP (cAMP) are reduced, resulting in a diminished rate of aqueous humor production.

Simultaneously, the alpha2 agonism modulates tissue in the uveoscleral outflow pathway , promoting increased drainage of the aqueous humor from the eye. This dual action—reduced production and enhanced drainage—is the causal mechanism for the resulting lower intraocular pressure (IOP). The molecule also causes localized vasoconstriction of anterior segment blood vessels, influencing local fluid exchange. Additionally, the mechanism engages pathways that may modulate excitotoxic signals, leading to an effect on retinal cell viability independent of the pressure-lowering action.

Dosage and Administration Information

How to Use Alphagan (Brimonidine Tartrate Ophthalmic Solution) — Administration and Dosing Guidelines

Alphagan is administered exclusively as a topical ophthalmic solution (eye drops) directly into the affected eye(s). Its use must strictly follow the dosing and administration rules established for this medication.


Dosing and Frequency Guidelines

Administration Scope Guideline
Route of Administration Topical Ophthalmic (Eye Drops)
Standard Dose One drop in the affected eye(s)
Frequency and Timing Three times a day (TID), spaced approximately 8 hours apart
Missed Dose If a dose is missed, the patient should skip that dose and return to the regular dosing schedule for the next application. Do not use a double dose

Administration Procedure and Constraints

Proper technique is required to prevent contamination and limit systemic absorption:

  • Contamination Avoidance: Do not allow the tip of the dispensing container to touch the eye or any surrounding surfaces.
  • Systemic Absorption Reduction: Immediately after instilling the drop, the lachrymal sac should be compressed at the inner corner of the closed eye (punctal occlusion) for about one minute. This helps reduce the amount of medication draining into the tear duct.
  • Other Eye Drops: If using other topical ophthalmic products, instill the different products at least five minutes apart.
  • Contact Lenses: Soft contact lenses must be removed before applying the drops. Wait at least 15 minutes after instillation before re-inserting the soft contact lenses.

Population-Specific Rules

  • Pediatric Use: Alphagan is contraindicated in neonates and infants (pediatric patients younger than 2 years of age).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alphagan

The research base for the active ingredient in Alphagan, brimonidine, includes study designs known as Randomized Controlled Trials (RCTs). These trials were primarily conducted in adult patients diagnosed with open-angle glaucoma or ocular hypertension (OHT), which are conditions characterized by elevated fluid pressure inside the eyeball. The research examined specific outcomes, primarily focusing on the measurement of the change in Intraocular Pressure (IOP), usually tracked in millimeters of mercury (mmHg), over defined time intervals.

Studies explored how IOP measurements varied at different times of the day, such as at the expected peak action of the eye drop and at its expected lowest point. Findings describe patterns observed in the studies where changes in IOP levels were monitored in the observed populations. Some reports indicate that brimonidine was observed in monotherapy (used alone) and as part of combination therapy (used alongside other eye drops), to examine IOP measurements in different treatment regimens.

Comparative trials have explored how the IOP measurements varied when brimonidine was evaluated against other common ocular antihypertensive agents. These studies are designed to measure the difference in IOP measurements between the treatments over a period of weeks or months.

Long-Term Studies and What is Still Uncertain

Clinical trials have monitored the effects of brimonidine over various periods, including long-term observation studies following cohorts for a year or more. Research has explored whether the observed patterns of IOP change were sustained throughout these extended monitoring periods.

Studies monitored the IOP measurements over these defined time intervals; some trials described patterns such as a diminished change in IOP measurements (sometimes called tachyphylaxis) in certain populations over time. Evidence for very long-term outcomes, extending multiple years, and the durability of the findings are not fully established across all studied groups. Furthermore, research for a separate outcome beyond IOP change, sometimes referred to as a neuroprotective effect, remains limited, and certainty remains low regarding its interpretation.

Key Studies & References Brimonidine Ophthalmic Solution: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Alphagan (FAQ)


Q: How quickly does Alphagan start to lower eye pressure after the first use?

According to official product information, the pressure-lowering effect of Alphagan begins shortly after application. Official product information notes that the peak pressure-lowering effect in clinical studies typically occurs about two hours after the drop is instilled.


Q: What is the difference between Alphagan P and regular Alphagan?

Both the original Alphagan solution (0.2%) and Alphagan P contain the same active ingredient, brimonidine tartrate. The primary difference lies in the preservative system used. Alphagan P utilizes a preservative called Purite®, whereas the older Alphagan 0.2% uses benzalkonium chloride (BAK).


Q: Is there a generic version of Alphagan available?

Yes, the active ingredient, brimonidine tartrate ophthalmic solution, is available in generic form. The generic versions contain the same active ingredient and are indicated for reducing elevated eye pressure.


Q: Can Alphagan cause changes in the color of the iris (the colored part of the eye)?

Official regulatory documentation for this medication does not list changes in the color of the iris as a reported adverse reaction. While discoloration of the white part of the eye or paleness of the eyelids have been reported in rare cases, iris color change is not among the documented side effects.


Q: Does using Alphagan make you more sensitive to light?

Increased sensitivity to light, known clinically as photophobia, has been reported as a less common side effect in some patients using this medication. Patients are advised to monitor for symptoms of increased light sensitivity while using the medication.


Q: Is it true that Alphagan can make the eye look lighter or bleached?

Official reports do not specifically use the terms 'lighter' or 'bleached' to describe changes in the eye. However, official post-marketing surveillance reports have, in rare cases, included reports of pallor (paleness) of the eyelid or the inner lining of the eye.


Q: What are the most common reasons a doctor would stop prescribing Alphagan?

Based on regulatory documentation summarizing clinical trials, the most frequent reasons noted for patients to stop treatment during clinical studies are often related to certain adverse reactions. These commonly include ocular allergic reactions (such as redness, itching, or burning) and systemic effects like dry mouth or drowsiness.


Q: Are there known food or drink interactions with Alphagan?

Regulatory documents do not mention any specific interactions between Alphagan and food. However, caution is advised regarding alcohol consumption. This is because alcohol may increase the risk of certain side effects, such as central nervous system (CNS) depression, which causes sedation or slowed reflexes.


Q: Can using Alphagan long-term affect my tear production?

Ocular dryness, commonly known as dry eyes, and keratoconjunctivitis sicca (a more severe form of dry eye disease) are listed in official documentation as known adverse reactions from the use of brimonidine.


Q: What should I do if my eye pressure is not decreasing after using Alphagan for a month?

Official research evidence notes that in some patients, the pressure-lowering effect may diminish over time. This phenomenon is sometimes referred to as tachyphylaxis. If the expected pressure reduction is lost or not achieved, the patient's prescribing health professional typically reviews the course of treatment.


Q: What are the ingredients that are inactive in the Alphagan formulation?

The inactive ingredients are included to maintain the stability and consistency of the eye drop solution. These typically include a buffer system (such as sodium borate and boric acid) and various salts (sodium chloride, potassium chloride, calcium chloride, and magnesium chloride), as noted in regulatory filings.


Q: Can using too much Alphagan cause additional side effects?

Yes, regulatory documents note that excessive use, whether topical or through accidental oral ingestion, can result in signs of systemic overdose. These effects may include low blood pressure (hypotension), slow heart rate (bradycardia), and severe central nervous system depression (somnolence).


Q: What percentage of people report experiencing eye irritation with Alphagan?

Official tables from clinical trials indicate that common ocular (eye) adverse events, such as allergic conjunctivitis (eye allergy), redness of the eye, and eye itching, were reported in a significant portion of patients. Specifically, these events were reported in approximately 10% to 20% of the individuals studied.


Q: Is it true that some versions of Alphagan use a disappearing preservative?

The product Alphagan P contains a specific type of preservative called Purite®. This preservative is considered an oxidizing preservative that is designed to convert into natural components of the tears, like water and salt, once it comes into contact with the eye, which may help diminish its effect on the ocular surface.


Q: Are there any restrictions on driving or operating machinery while using Alphagan?

Alphagan may cause side effects such as drowsiness, fatigue, or blurred vision. Official labeling advises caution with activities like driving or operating machinery because the medication may cause these visual or systemic effects.


Q: Does Alphagan interact with common over-the-counter medications?

Official regulatory advice cautions against using Alphagan alongside any medicine that can potentially lower blood pressure or cause sedation/drowsiness. This warning is due to the potential for the combined effect of the medications to increase side effects.


Q: Does my diet or lifestyle affect how Alphagan works?

Regulatory information specifically highlights alcohol consumption as a lifestyle factor requiring caution. Official information states this warning is due to the potential for the risk of certain side effects, particularly those affecting the central nervous system like sedation and lightheadedness, to increase.


Q: Is there a maximum amount of time Alphagan is approved for use?

Alphagan is indicated for the treatment of elevated eye pressure. Regulatory labeling does not state a specific, defined maximum duration of treatment for its use in managing eye pressure.


Q: What are the signs of an allergic reaction to Alphagan?

Common signs of an ocular allergic reaction include eye pruritus (itching), redness of the eye, and swelling of the eye surface. Signs of a severe systemic allergic reaction may include swelling of the face, difficulty breathing, rash, hives, or syncope (fainting), as noted in post-marketing surveillance.


Q: Why is the shelf life of Alphagan drops mentioned on the packaging?

The shelf life and storage conditions are defined and mandated by regulatory agencies. This is done to ensure the product remains sterile and that the active ingredient's stability and therapeutic effectiveness are reliably maintained until the printed expiry date.


Q: Are there different concentrations of Alphagan drops available?

Yes, the active ingredient, brimonidine tartrate ophthalmic solution, is available in different prescription strengths. These include concentrations of 0.1%, 0.15% (often Alphagan P), and the original 0.2% strength.


Q: What is the general expected duration of action for one dose of Alphagan?

Official regulatory documents indicate a typical dosing frequency of three times daily, spaced approximately 8 hours apart. This frequency is based on the therapeutic duration of action for the medication.


Q: Does Alphagan contain any preservatives like benzalkonium chloride (BAK)?

The original Alphagan (0.2%) formulation contains the preservative benzalkonium chloride (BAK). However, the product Alphagan P was formulated to use the preservative Purite® as an alternative to BAK.


Q: Is Alphagan used for all types of glaucoma?

Official documentation indicates that Alphagan is specifically approved for reducing elevated fluid pressure inside the eye in patients with open-angle glaucoma or ocular hypertension. It is not broadly indicated for all different types of glaucoma conditions.


Q: How does Alphagan compare to other types of eye pressure-lowering drops, generally speaking?

Clinical trials summarized in regulatory documents compared Alphagan to other ocular pressure-lowering agents, such as timolol. These studies indicated that Alphagan's efficacy in reducing intraocular pressure was generally similar to that of these comparator drugs when administered twice daily.


Q: Why is it important to wait before putting contact lenses back in after using the drops?

Soft contact lenses must be removed before the drop is applied because the preservative, such as benzalkonium chloride, can be absorbed by the lens material. Official instructions require that lenses not be reinserted for at least 15 minutes after instillation to prevent this absorption.


Q: How does the action of Alphagan differ from other prostaglandin analogs?

Alphagan, which is an alpha-2 adrenergic agonist, works mainly by reducing the rate at which internal eye fluid (aqueous humor) is produced. In contrast, prostaglandin analogs work primarily by significantly increasing the drainage of this fluid from the eye.

How should Alphagan be stored and disposed of?

How to Store and Dispose of Alphagan?

Storing Alphagan (Brimonidine Tartrate Ophthalmic Solution) requires adherence to specific conditions detailed in the official prescribing information to maintain product integrity and safety.

Official Storage Requirements

Condition Regulatory Statement
Temperature Store at 15 C to 25 C (59 F to 77 F). Do not freeze.
Protection Keep the container tightly closed and store away from excess heat, moisture, and direct light.
Safety Keep the medicine out of the sight and reach of children.
Stability Discard the bottle 28 days after the date of first opening.

Disposal Instructions

Disposing of unused or expired Alphagan must follow regulatory guidelines. The solution must not be discarded via household waste or poured down a sink or drain (wastewater). Patients are instructed to consult a pharmacist or healthcare professional for the proper local procedure for drug disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alphagan found in:

A-Z Index: